

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (Original) A regime or regimen for inhibiting NO-synthase, comprising administering to an individual in need of such treatment, a thus effective amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.
  
2. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus slowing or inhibiting cell differentiation and/or proliferation, comprising administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.
  
3. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus slowing or inhibiting the growth of the epidermis and/or ~~for~~ treating hyperproliferation disorders, comprising administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine, or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.
  
4. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus inhibiting the degradation and/or destruction of cells, comprising

administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine, or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.

5. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus inhibiting a cellular apoptotic process, comprising administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine, or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.

6. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus treating intrinsic and/or extrinsic aging, comprising administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine, or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.

7. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus inhibiting or suppressing an immunological and/or inflammatory process, comprising administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine, or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.

8. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus treating a contact hypersensitivity reaction and/or an allergic manifestation and/or an immune response, comprising administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine, or

therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.

9. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus treating a skin reaction neurogenic in origin, comprising administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine, or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.

10. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus treating "sensitive skin," comprising administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine, or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.

11. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus increasing the barrier effect or moisturization of the skin, comprising administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine, or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.

12. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus treating erythema, comprising administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine, or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.

13. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus treating a localized or diffuse erythematous skin rash, comprising administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine, or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.

14. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus treating rosacea, comprising administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine, or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.

15. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus inhibiting melanogenesis ~~induces~~ induced by UV-A and/or UV-B radiation and/or ~~for~~ treating a hypermelanosis disorder, comprising administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine, or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.

16. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus controlling sweating, comprising administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine, or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.

17. (Currently Amended) A regime or regimen for inhibiting NO-synthase and thus inhibiting hair loss, comprising administering to an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of

N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine, or therapeutic/cosmetic composition comprised thereof, formulated into a physiologically acceptable medium therefor.

18. (Original) The regime or regimen as defined by Claim 1, comprising administering a therapeutic/cosmetic composition which comprises from  $10^{-4}\%$  to 20% by weight of said N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine.

19. (Original) The regime or regimen as defined by Claim 1, comprising administering a therapeutic/cosmetic composition which comprises from  $5 \times 10^{-3}\%$  to 10% by weight of said N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine.

20. (Currently Amended) A cosmetic regime or regimen for treating a disorder associated with NO-synthesis, comprising topically applying onto the skin, the hair and/or the mucous membranes of an individual in need of such treatment, a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine formulated into a topically applicable, physiologically acceptable medium therefor.

21. (Currently Amended) A therapeutic/cosmetic composition suited for treating a disorder associated with NO-synthesis, comprising a thus effective NO-synthase inhibiting amount of N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine formulated into a physiologically acceptable medium therefor and constituting a cream, a gel, a serum, a lotion, a milk, a sunscreen, an emulsion, a mousse, an aerosol, a shampoo, a cleaning bar, a soap, a toothpaste, a syrup, capsules, tablets, granules, microcapsules, microparticles, or a vesicular dispersion.

22. (Original) The therapeutic/cosmetic composition as defined by Claim 21, further comprising at least one other NO-synthase inhibitor.

23. (Original) The therapeutic/cosmetic composition as defined by Claim 21, further comprising at least one other active agent selected from the group consisting of an agent for modifying cutaneous differentiation and/or proliferation and/or pigmentation; an antibacterial agent; an antiparasitic agent; and antifungal agent; a nonsteroidal anti-inflammatory agent; a keratolytic agent; a free-radical scavenger; an antiseborrheic agent; an antidandruff agent; an antiacne agent; an extract of plant or microbial origin; and a peptide or derivative thereof.

24. (New) The regime or regimen as defined by Claim 15, wherein a therapeutic/cosmetic composition comprising from  $10^{-4}\%$  to 20% by weight of said N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine is administered.

25. (New) The regime or regimen as defined by Claim 15, wherein a therapeutic/cosmetic composition comprising from  $5 \times 10^{-3}\%$  to 10% by weight of said N,N'-bis(2-pyridyl)methyl-N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine is administered.